ATLANTA, June 18, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Zentalis Pharmaceuticals, Inc. ("Zentalis"?or the "Company") (NASDAQ:ZNTL) complied with federal securities laws. On June 18, 2024, Zentalis announced that "the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 ...
ZNTL) Announced byHolzer & Holzer, LLC>Full story available on Benzinga.com